Xtandi (enzalutamide; Pfizer/Astellas) is an androgen receptor (AR) signaling inhibitor that inhibits the AR at three distinct points in the signaling pathway. Xtandi competitively inhibits binding of the androgens to the AR, inhibits AR nuclear translocation, and inhibits association of the AR with DNA. In preclinical studies, Xtandi was shown to provide a more complete suppression of the AR than Casodex (bicalutamide; AstraZeneca).
TABLE OF CONTENTS
4 Product Profiles
4 Xtandi : Prostate cancer
LIST OF FIGURES
10 Figure 1: Xtandi for prostate cancer – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of Xtandi for prostate cancer
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of Xtandi for prostate cancer
15 Figure 4: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
4 Table 1: Xtandi drug profile
6 Table 2: Xtandi Phase III data in prostate cancer
8 Table 3: Xtandi Phase III trials in prostate cancer
16 Table 4: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.